FimmCyte proudly claims a spot in the prestigious 2024 TOP 100 Swiss Startup Award, ranking #28 overall and achieving 4th place in the biotech sector. Selected by a panel of 100 leading investors and industry experts, this recognition highlights FimmCyte’s groundbreaking work in addressing endometriosis, a condition affecting 1 in 10 women worldwide.
With limited treatment options and significant side effects from existing therapies, FimmCyte’s innovative approach offers new hope. Early results in lab and animal studies demonstrate the potential to revolutionize care for this painful, life-altering condition. The company is committed to advancing its treatment to clinical trials, aiming to improve women’s health on a global scale.
This year, the biotech sector shone at the TOP 100 Swiss Startup Award, with 15 remarkable companies featured. The recognition of FimmCyte underscores the growing impact of Swiss biotech innovation in transforming life sciences and addressing unmet medical needs.
